Йорданія - англійська - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - siponimod 0.25 mg - 0.25 mg

Йорданія - англійська - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - siponimod 0.25 mg - 0.25 mg

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - siponimod fumarate 0.278mg equivalent to siponimod 0.25mg - film coated tablet - 0.25 mg - active: siponimod fumarate 0.278mg equivalent to siponimod 0.25mg excipient: colloidal silicon dioxide crospovidone glyceryl dibehenate iron oxide black iron oxide red lactose monohydrate lecithin microcrystalline cellulose polyvinyl alcohol purified talc titanium dioxide xanthan gum - mayzent® is indicated for the treatment of patients with secondary progressive multiple sclerosis (spms).

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - siponimod fumarate 2.024mg equivalent to siponimod 2mg - film coated tablet - 2 mg - active: siponimod fumarate 2.024mg equivalent to siponimod 2mg excipient: colloidal silicon dioxide crospovidone glyceryl dibehenate iron oxide red iron oxide yellow lactose monohydrate lecithin microcrystalline cellulose polyvinyl alcohol purified talc titanium dioxide xanthan gum - mayzent® is indicated for the treatment of patients with secondary progressive multiple sclerosis (spms).

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - siponimod fumarate 1.112mg equivalent to siponimod 1mg - film coated tablet - 1 mg - active: siponimod fumarate 1.112mg equivalent to siponimod 1mg excipient: colloidal silicon dioxide crospovidone glycerol dibehenate xanthan gum iron oxide black iron oxide red lactose monohydrate lecithin microcrystalline cellulose polyvinyl alcohol purified talc titanium dioxide - mayzent is indicated for the treatment of patients with secondary progressive multiple sclerosis (spms).

Канада - англійська - Health Canada

novartis pharmaceuticals canada inc - ruxolitinib (ruxolitinib phosphate) - tablet - 5mg - ruxolitinib (ruxolitinib phosphate) 5mg - antineoplastic agents

Канада - англійська - Health Canada

novartis pharmaceuticals canada inc - ruxolitinib (ruxolitinib phosphate) - tablet - 15mg - ruxolitinib (ruxolitinib phosphate) 15mg - antineoplastic agents

Канада - англійська - Health Canada

novartis pharmaceuticals canada inc - ruxolitinib (ruxolitinib phosphate) - tablet - 20mg - ruxolitinib (ruxolitinib phosphate) 20mg - antineoplastic agents

Канада - англійська - Health Canada

novartis pharmaceuticals canada inc - ruxolitinib (ruxolitinib phosphate) - tablet - 10mg - ruxolitinib (ruxolitinib phosphate) 10mg - antineoplastic agents

ПАР - англійська - South African Health Products Regulatory Authority (SAHPRA)

novartis south africa (pty) ltd - tablet - see ingredients - each tablet contains siponimod 0,25 mg